Aanjaneya Lifecare sales jumps by 50% to Rs.480 cr

Aanjaneya Lifecare has posted strong top line growth during the year ended March 2012 and its net sales increased by 50 per cent to Rs.479.96 crore from Rs.320.26 crore in the previous year. Its net profit improved by 13.9 per cent to Rs.41.03 crore from Rs.36.01 crore. After taking into consideration the rise in equity capital, its earnings per share worked out to Rs.34.42 as compared to Rs.52 in the previous year.

Its EBDITA went up to Rs.107.76 crore from Rs.70.85 crore, a significant growth of 52.1 per cent. The company recommended equity dividend of 20 per cent for the year 2011-12. The company has manufacturing and marketing capabilities in APIs with focus on anti-malarial, CRAMS and finished dosage forms catering to various therapeutic segments.

Dr Kannan Vishwanath, managing director, said, “It has been a very promising year for the company, one in which we could achieve our goals set towards customer satisfaction, quality standards and of course shareholder value. We are on the path of expansion, with recent acquisition of Apex Drugs & Intermediates Ltd giving us an entry in Hyderabad market.”

The company raised about Rs.117 crore from its IPO and the funds are being used to built new capacities along with the refurbishing of R&D centre and CRAMS centre. The new facilities being created as part of CAPEX will comply with the latest European & US guidelines. With new capacities to be added in next 6 to 9 months the company will be expanding operations in emerging markets of South East Asia, Africa and South & Central America and its domestic operations in branded generics segment.

The company's equity capital increased to Rs.13.89 crore during 2011-12 from Rs.7.58 crore in the previous year as the company issued 13,10,484 shares of Rs.10 each at premium of Rs.486 per share to other than promoter on a preferential basis. Currently, the Aanjaneya scrip is moving aroundRs.525 on BSE.